Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if an FDA-approved drug (Gralise) can help people with certain types of neuropathic pain without causing too many side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Gralise to Treat Fibromyalgia Patients

NCT02052414

Fibromyalgia

COMPLETED NA

Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia

NCT01426230

Post Herpetic Neuralgia

COMPLETED

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911

Irritable Bowel Syndrome Ulcerative Colitis Interstitial Cystitis +2 more

TERMINATED PHASE4

Once Daily Gabapentin in the Treatment of Post Amputation Pain

NCT01776671

Pain Quality of Life

UNKNOWN PHASE3

Comparison of Gabapentin and Pregabalin for Radicular Pain

NCT02064790

Radicular; Neuropathic, Lumbar, Lumbosacral Radicular; Neuropathic, Cervical

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research is being conducted to see if the drug Gralise can help people with Complex Regional Pain Syndrom Type I (CRPS I) without causing too many side effects. CRPS I is one of the most common conditions of neuropathic pain (pain that results from damage to nerves in the peripheral nervous system). Gralise is approved by the U.S. Food and Drug Administration (FDA) to treat postherpetic neuralgia (a complication of the disease Shingles, which is caused by the chickenpox virus), but is not approved to treat CRPS I.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complex Regional Pain Syndrome I (CRPS I)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CRPS I Pain Subjects

This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.

Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day

Group Type EXPERIMENTAL

Gabapentin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gabapentin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gralise

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject will be between 18 to 80 years of age.
2. Subject has not been on Gralise.
3. Subject has not been on gabapentin for at least one month.
4. Subject agrees to make no change in his/her current pain medications during the study period to ensure that comparisons can be made before and after the Gralise treatment.
5. Subject has a VAS pain score of 5 or above at the beginning of the study.
6. Subject has had CRPS I for at least three months to avoid clinical uncertainty and minimize the study variation.
7. Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.

Exclusion Criteria

1. Subject has severe liver or renal disease that will affect the elimination of Gralise. (Renal dysfunction is defined as eGFR \< 60. Hepatic dysfunction is defined as LFTs ≥ 3X ULN.)
2. Subject has pending litigation related to his/her CRPS I condition.
3. Subject is pregnant or lactating.
4. Subject is allergic to gabapentin or Gralise.
5. Subject has a positive urine (illicit) drug test.
6. Subject has any history of suicidal thoughts or behaviors, as self reported or in documented medical history.
7. Subjects with known seizure disorders (except febrile seizures) and/or taking antiepileptic drugs.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No